收稿日期: 2025-07-10
网络出版日期: 2025-12-18
基金资助
新疆维吾尔自治区自然科学基金-青年基金项目(2024D01C288)
Correlation between atherogenic index of plasma and prognosis of patients with acute myocardial infarction
Received date: 2025-07-10
Online published: 2025-12-18
目的 探讨基线血浆致动脉粥样硬化指数(AIP)对急性心肌梗死(AMI)患者长期预后的影响。 方法 连续纳入2018年1月至2019年12月期间新疆维吾尔自治区人民医院收治的712例AMI患者作为研究对象,依据AIP三分位数将研究对象分为低值组(AIP < 0.280,n = 237),中值组(AIP 0.280 ~ 0.852,n = 238)和高值组(AIP > 0.852, n = 237)。终点事件定义为主要心血管不良事件(MACEs)的发生。采用多因素Cox回归分析MACEs发生的独立影响因素;采用限制性立方样条图分析AIP与MACEs发生风险之间的非线性关系;采用Kaplan-Meier曲线分析组间生存差异;亚组分析评估AIP对MACEs预测价值的一致性。 结果 随着AIP三分位数分组递增,患者血脂异常和MACEs发生比例升高,白细胞计数、空腹血糖、甘油三酯、总胆固醇、低密度脂蛋白、AIP升高,高密度脂蛋白降低 (P ? 0.05)。多因素Cox回归分析结果显示:AIP是MACEs 发生的独立危险因素(HR = 2.024,95%CI:1.211 ~ 3.381,P = 0.007)。限制性立方样条图分析结果显示:AIP与MACEs发生风险之间呈“L”形非线性效应关系(P-Nonlinear = 0.008),当AIP > 0.613时,AMI患者MACEs风险随AIP升高而升高。Kaplan-Meier生存曲线分析结果显示:随着AIP升高AMI患者MACEs累积发生率显著增加(Log-rank test,P = 0.032),与低值组相比,高值组患者MACEs发生风险增加131%(HR = 2.311,95%CI:1.261 ~ 4.234,P = 0.007)。亚组分析结果显示,各亚组内交互作用P值均不显著,AIP对MACEs预测能力适用于所有亚组人群。 结论 基线AIP升高是AMI患者远期不良预后的独立危险因素。
关键词: 血浆致动脉粥样硬化指数; 急性心肌梗死; 危险因素; 预后
王凯阳 , 永佳蕙 , 陶静 , 沈鑫 . 血浆致动脉粥样硬化指数对急性心肌梗死患者长期预后的影响[J]. 实用医学杂志, 2025 , 41(23) : 3697 -3703 . DOI: 10.3969/j.issn.1006-5725.2025.23.010
Objective To investigate the effect of baseline atherogenic index of plasma (AIP) on the long-term prognosis of patients with acute myocardial infarction (AMI). Methods A total of 712 AMI patients admitted to the hospital from January 2018 to December 2019 were continuously included as subjects and divided into a low-value group (AIP < 0.280, n = 237), a median-value group (AIP 0.280 ~ 0.852, n = 238) and a high-value group (AIP > 0.852, n = 237) according to the baseline AIP tertiles. The primary endpoint was defined as the occurrence of major cardiovascular adverse events (MACEs). Multivariate Cox regression was used to analyze the independent influencing factors of MACEs. The nonlinear relationship between AIP and the risk of MACEs was analyzed with restricted cubic spline plots. Kaplan-Meier curve was used to analyze survival differences between groups. Subgroup analysis assesses the consistency of AIP's predictive value to MACEs. Results With the increase of AIP tertile groups, the proportion of dyslipidemia and MACEs increased, white blood cell count, fasting blood glucose, triglyceride, total cholesterol, low density lipoprotein and AIP increased, and high-density lipoprotein decreased, with statistical significance (P < 0.05). Multivariate Cox regression analysis showed that AIP was an independent risk factor for MACEs (HR = 2.024, 95%CI: 1.211 ~ 3.381, P = 0.007). The results of restricted cubic spline analysis show that there is an L-shaped nonlinear effect relationship between AIP and the risk of MACEs (P-nonlinear = 0.008). When AIP > 0.613, the risk of MACEs in AMI patients increases with the increase of AIP. Kaplan-Meier survival curve analysis results show: With the increase of AIP, the cumulative incidence of MACEs in AMI patients increased significantly (Log-rank test, P = 0.032). Compared with the low-value group, the risk of MACEs in the high-value group increased by 131% (HR = 2.311, 95%CI: 1.261 ~ 4.234, P = 0.007). The results of subgroup analysis showed that the P value of interaction within each subgroup was not significant, and the ability of AIP to predict MACEs was applicable to all subgroups. Conclusion Increased AIP at baseline is an independent predictor of poor long-term prognosis in patients with AMI.
| [1] | 中国心血管健康与疾病报告编写组, 胡盛寿. 中国心血管健康与疾病报告2022概要[J]. 中国循环杂志, 2023, 38(6): 583-612. doi:10.3969/j.issn.1000-3614.2023.06.001 |
| [2] | 苏州工业园区东方华夏心血管健康研究院, 中国医师协会胸痛专业委员会, 霍勇,等. 《胸痛中心质控报告(2022)》概要[J]. 中国介入心脏病学杂志, 2023, 31(11): 820-827. |
| [3] | 新华社. 中共中央国务院印发《"健康中国2030"规划纲要》[J]. 中华人民共和国国务院公报, 2016(32): 5-20. |
| [4] | 中国血脂管理指南修订联合专家委员会, 李建军, 赵水平,等. 中国血脂管理指南(2023年)[J]. 中国循环杂志, 2023, 38(3): 237-271. |
| [5] | 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51(3): 221-255. |
| [6] | 王雪华, 李红建. 血浆致动脉硬化指数的临床研究进展[J]. 中国动脉硬化杂志, 2022, 30(5): 449-453. |
| [7] | WON K B, HEO R, PARK H B, et al. Atherogenic index of plasma and the risk of rapid progression of coronary atherosclerosis beyond traditional risk factors[J]. Atherosclerosis, 2021, 324: 46-51. doi:10.1016/j.atherosclerosis.2021.09.004 |
| [8] | 吕素洁, 吴寿岭, 朱辰蕊,等. 血浆致动脉粥样硬化指数对急性心肌梗死发生的预测价值[J]. 中国心血管杂志, 2024, 29(1): 40-45. |
| [9] | BYRNR R A, ROSSELLO X, COUGHLAN J J, et al. 2023 ESC Guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44(38): 3720-3826. |
| [10] | WANG K Y, ZHENG Y Y, WU T T, et al. Predictive Value of Gensini Score in the Long-Term Outcomes of Patients With Coronary Artery Disease Who Underwent PCI[J]. Front Cardiovasc Med, 2021, 8: 778615. doi:10.3389/fcvm.2021.778615 |
| [11] | REYNOLDS H R, SHAW L J, MIN J K, et al. Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity[J]. Circulation, 2021, 144(13): 1024-1038. doi:10.1161/circulationaha.120.049755 |
| [12] | 中国高血压防治指南修订委员会, 高血压联盟(中国,等.中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志(中英文), 2024, 32(7): 603-700. |
| [13] | 李沛城, 冯波. 《中国糖尿病防治指南(2024版)》更新要点解读[J]. 同济大学学报(医学版), 2025, 46(2): 151-158. |
| [14] | 王增武, 刘静, 李建军, 等. 中国血脂管理指南(2023年)[J]. 中国循环杂志, 2023, 38(3): 237-271. |
| [15] | 国家卫生健康委员会肥胖症诊疗指南编写委员会. 肥胖症诊疗指南(2024年版)[J]. 中国循环杂志, 2025, 40(1): 6-30. |
| [16] | 刘明波, 何新叶, 杨晓红, 等. 《中国心血管健康与疾病报告2024》要点解读[J]. 实用医学杂志, 2025, 41(14): 2111-2131. |
| [17] | WANG L, CHEN F, CHAI Xet al. Atherogenic Index of Plasma Is an Independent Risk Factor for Coronary Artery Disease and a Higher SYNTAX Score[J]. Angiol J Vascr Dis, 2021, 72(2): 309-321. doi:10.1177/0003319720949804 |
| [18] | NEELAND I J, ROSS R, DESPRES J P, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement[J]. Lancet Diabetes Endocrinol, 2022, 7(9): 715-725. |
| [19] | 王凯阳, 陶静, 吴婷婷, 等. 新型人体测量学指标与急性心肌梗死患者长期预后的相关性[J]. 实用医学杂志, 2024, 40(21): 3040-3046. |
| [20] | ZHU X, YU L, ZHOU H, et al. Atherogenic index of plasma is a novel and better biomarker associated with obesity: a population-based cross-sectional study in China[J]. Lipids Health Dis, 2022, 17(1): 1126-1138. |
| [21] | LI Y W, KAO T W, CHANG P K, et al. Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: A 9-year longitudinal study[J]. Sci Rep, 2021, 11(1): 206-218. doi:10.1038/s41598-021-89307-z |
| [22] | YIN B, WU Z, XIA Y, et al. Non-linear association of atherogenic index of plasma with insulin resistance and type 2 diabetes: A cross-sectional study[J]. Cardiovasc Diabetol, 2023, 22(1): 157. doi:10.1186/s12933-023-01886-5 |
| [23] | ZHENG G, JIN J, WANG F, et al. Association between atherogenic index of plasma and future risk of cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: A nationwide prospective cohort study[J]. Cardiovasc Diabetol, 2025, 24(1): 22. doi:10.1186/s12933-025-02589-9 |
| [24] | BALLING M, NORDESTGAARD B G, VARBO A, et al. Small Dense Low-Density Lipoprotein Cholesterol and Ischemic Stroke[J]. Ann Neurol, 2023, 93(5): 952-964. doi:10.1002/ana.26598 |
| [25] | ARAI T, SEKIMOTO T, KOBA S, et al. Impact of small dense low-density lipoprotein cholesterol and triglyceride-rich lipoproteins on plaque rupture with ST-segment elevation myocardial infarction[J]. J Clin Lipidol, 2022, 16(5): 725-732. doi:10.1016/j.jacl.2022.07.012 |
/
| 〈 |
|
〉 |